01.10.25 -- FDA: Nonclinical Safety Assessment Of Oligonucleotide-Based Therapeutics

We’re ready to help usher your next drug into market! 2025’s first Outsourced Pharma Capacity Update provides a unique, virtual experience and the details necessary to find a CDMO for your specific timeline, volume, and production needs. Join us the last week of January as we draw the curtains on the industry’s best and give you complimentary VIP access to the resources available to support your success. Learn more and register to save your seat!

This past year sent us a harsh reminder: None of us are paragons of outsourcing sagacity. We need to keep learning, updating, and staying aware that the outside world – history in the making– interferes. Here's a review of a historic year that will get you thinking: How did I create outsourcing history in 2024?

Explore key considerations for ensuring accuracy and efficiency in your labeling process, from robust control systems to diverse printing options and comprehensive qualification.

If you’re launching an international clinical trial, consider the noteworthy benefits of partnering with an in-country depot, including increased efficiency, reduced costs, and reliable access to raw materials.

Devoting early-phase resources for solid form understanding and screening during a drug’s development lifecycle is critical, as doing so can help save time and resources on the path to market.

When developing a nasal delivery program, a partner with experience in development and manufacturing techniques who can see a program through small-scale clinical to commercial supply is crucial.

Contamination Control Strategies (CCS) have long been a main concept, but advancing requirements and regulatory expectations create a challenge. Learn how to be effective and compliant with your CCS.

Examine a new methodology that holds significant promise for identifying APIs at risk for NDSRI formation, enabling manufacturers to prioritize risk mitigation strategies and ensure compliance.

Review the results of this study and learn how KinetiSol Solid Dispersion lowered patients' pill burdens and demonstrated an improved therapeutic response for Galeterone.

Use our services and solutions to advance small molecule development — from initial design and optimization to full-scale manufacturing and comprehensive analytical support.

Pinpoint impurities and conduct confirmatory testing under cGMP with the help of an expert team utilizing cutting-edge mass spectrometry technology to boost your drug product development.

Experience how a global network and cost-efficient model can simplify outsourcing for your discovery, preclinical, clinical, and commercial NCE programs.